Publications by authors named "Evelin Feher"
Background: Biomarkers for predicting treatment response to thrombolysis in acute ischemic stroke are currently lacking. Both, animal models and clinical studies have provided evidence that the kynurenine (KYN) pathway is activated in ischemic stroke.
Objectives: In our pilot study, we aimed to investigate whether KYN pathway enzymes and metabolites could serve as potential biomarkers for treatment response in the hyperacute phase of ischemic stroke.
Article Synopsis
- The study explores how enhancing the Cincinnati Prehospital Stroke Scale (CPSS) can improve the detection of large vessel occlusion (LVO) in patients suffering from acute ischemic strokes (AIS).
- Researchers developed a detailed version of CPSS (d-CPSS) to better assess stroke severity using the National Institutes of Health Stroke Scale (NIHSS) as a benchmark.
- Results showed that the d-CPSS had a higher accuracy in identifying LVO compared to the regular CPSS and was nearly as effective as NIHSS, with a recommended cut-off score of 5 for diagnosis.
Kynurenic acid (KYNA), a metabolite of tryptophan, as an excitatory amino acid receptor antagonist is an effective neuroprotective agent in case of excitotoxicity, which is the hallmark of brain ischemia and several neurodegenerative processes. Therefore, kynurenine pathway, KYNA itself, and its derivatives came into the focus of research. During the past fifteen years, our research group has developed several neuroactive KYNA derivatives, some of which proved to be neuroprotective in preclinical studies.
View Article and Find Full Text PDF